

Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â Â FORM 6-
KÂ Â Report of Foreign Private IssuerPursuant to Rule 13a-16 or 15d-16Under the Securities Exchange Act of
1934Â For the month of February 2025Â Commission File Number 001-40772Â Â Cellebrite DI Ltd.(Translationof
registrantâ€™s name into English)Â Â 94 Shlomo Shmelzer RoadPetah Tikva 4970602, Israel(Address of principal
executive office)Â Â Indicate by check mark whether the registrant files or will file annualreports under cover Form
20-F or Form 40-F.Â Form 20-F â˜ Form 40-F â˜Â Â Â Â EXPLANATORY NOTEÂ On February 13, 2025,
CellebriteDI Ltd. (the â€œRegistrantâ€ or â€œCellebriteâ€) issued a press release titled â€œCellebrite Announces
Fourth-Quarterand Full-Year 2024 Results.â€ A copy of this press release is furnished as Exhibit 99.1 herewith.Â The
GAAP financial statements tables contained in the press releaseattached to this report on Form 6-K are incorporated by
reference into the Registrantâ€™s registration statements on Form S-8 (FileNos. 333-260878 and 333-278130) filed
with the U.S. Securities and Exchange Commission (the â€œSECâ€) on November 8, 2021 andMarch 21, 2024,
respectively, and Form F-3 (File No. 333-259826) filed with the SEC on September 13, 2022.Â 1 Â Â EXHIBIT
INDEXÂ Exhibit Â Description 99.1 Â Press release titled â€œCellebrite Announces Fourth-Quarter and Full-Year
2024 Resultsâ€ (furnished herewith). Â 2 Â Â SIGNATURESÂ Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.Â Â Â Cellebrite DI Ltd. Â Â Â Date: February 13, 2025 By: /s/ Dana Gerner Â Â Dana Gerner Â Â Chief
Financial Officer Â Â 3Â Â Exhibit 99.1Â Â Â Cellebrite Announces Fourth-Quarter and Full-Year2024
ResultsÂ Companydelivers â€œRule of 50â€ Performance in 2024 with 25% ARR growth and 25% adjusted EBITDA
marginÂ Fourth-quarter2024 revenue of \$109.0 million grew 17% primarily due to21% growthin subscription
revenueÂ ARR grew25% to \$395.9 millionÂ Fourth-quarter2024 adjusted EBITDA of \$28.8 million, 26.4% adjusted
EBITDA marginÂ TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, February 13, 2025 â€œCellebrite (NASDAQ:
CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today
announcedfinancial results for the three and twelve months ending December 31, 2024.Â â€œCellebrite delivered a
solid fourth-quarter performance to cap anexcellent 2024 in which we exceeded our original revenue and adjusted
EBITDA targets and delivered at the higher end of our ARR expectations,â€ stated Thomas E. Hogan, Cellebriteâ€™s
interim chief executive officer. â€œWe enjoyed continued success in expanding our share-of-walletacross our global
installed base and converting that top-line growth into meaningful year-over improvement in our profitability and
freecash flow. As a result, we produced a Rule of 50 performance in 2024 with 25% ARR growth and 25% adjusted
EBITDA margins. With multiplemacro tailwinds that we believe show no signs of dissipating, we move into 2025 with
plans to advance our market and technology leadership,sustain our top-line expansion and continue generating
attractive profit margins and robust free cash flow.â€Â Fourth-Quarter 2024 Financial HighlightsÂ —Revenue of
\$109.0 million, up 17% year-over-yearÂ —Subscription revenue was \$95.1 million, up 21% year-over-yearÂ —Annual
Recurring Revenue (ARR) of \$395.9 million, up 25% year-over-yearÂ —Recurring revenue dollar-based net retention
rate of 124%Â —GAAP gross profit and gross margin of \$91.4 million and 83.8%, respectively; Non-GAAP gross profit
and gross profit margin of \$92.0million and 84.4%, respectivelyÂ —GAAP net income of \$19.3 million; Non-GAAP net
income of \$26.1 millionÂ —GAAP diluted earnings per share of \$0.08; Non-GAAP diluted earnings per share of
\$0.10Â —Adjusted EBITDA and Adjusted EBITDA margin of \$28.8 million and 26.4%, respectivelyÂ Â Â Full-Year
2024 Financial HighlightsÂ —Revenue of \$401.2 million, up 23% year-over-yearÂ —Subscription revenue was \$353.0
million, a 26% year-over-year increaseÂ —GAAP gross profit and gross margin of \$338.6 million and 84.4%,
respectively; Non-GAAP gross profit and gross profit margin of \$340.8million and 85.0%, respectivelyÂ —GAAP net
loss of \$283.0 million; Non-GAAP net income of \$97.8 millionÂ —GAAP diluted loss per share of \$1.35; Non-GAAP
diluted earnings per share of \$0.42Â —Adjusted EBITDA and adjusted EBITDA margin of \$99.4 million and 24.8%,
respectivelyÂ Fourth-Quarter 2024 and Recent Business &Operational HighlightsÂ Board GovernanceÂ —OnJanuary 6,
2025, Cellebrite announced a series of Boardupdates to support the Companyâ€™s continued growth into 2025and
beyond.Â oThomas E. Hogan, previously Cellebriteâ€™s executive chairman, was appointed interim chief executive
officer and will remain onthe Companyâ€™s Board of Directors.Â oAdam H. Clammer, Managing Partner of True Wind
Capital Management and Cellebriteâ€™s current lead independent director, succeededHogan as board chairman. It is
expected that Hogan will revert to board chairman upon the eventual appointment of a new CEO.Â oMichael D.
Capellas, a distinguished executive with extensive leadership experience across a range of CIO, CEO and board
chairmanand director positions at a number of the worldâ€™s most successful software and technology companies, has
been appointed to Cellebriteâ€™sBoard of Directors as a Class II director and will serve as the Boardâ€™s lead
independent director.Â Go-to-Market Â —On February 11, 2025, Cellebrite published its sixth annual 2025
IndustryTrends Survey, highlighting how public safety professionals use and apply powerful digital investigative
solutions to uncover digitalevidence in criminal investigations and revealing widespread appetite for artificial
intelligence and cloud solutions.Â Innovation Â —On February 12, 2025, Cellebrite announced that its
CellebriteGovernment Cloud platform has achieved FedRAMPHigh Ready designation by the Federal Risk and
Authorization Management Program (FedRAMP). This milestone, which marks the initialstage in the compliance
process, reinforces Cellebriteâ€™s commitment to equipping and empowering its U.S. federal customers withindustry-
leading cloud security when utilizing the Companyâ€™s Software-as-a-Service-based digital investigative solutions.Â 2
Â Â Â —On February 6, 2025, Cellebrite announced the general availabilityof GenerativeArtificial Intelligence (GenAI)
capabilities within Guardian, Cellebriteâ€™s SaaS-based evidence management solution.Â —On November 20, 2024,
as part of an exclusive technologyand go-to-market partnership with Relativity, Cellebrite announced that it had
integratedits mobile collection solutions, Endpoint Inspector and Endpoint Mobile Now, into the RelativityOne
platform.Â Supplemental financial information can be found onthe Investor Relations section of our website
atÂ <https://investors.cellebrite.com/financial-information/quarterly-results>.Â Financial OutlookÂ â€œCellebriteâ€™s
2024 financial results reflect a balanced mixof top-line growth and strong profitability,â€ stated Dana Gerner,
Cellebriteâ€™s chief financial officer. â€œRedeeming ourwarrants and hitting various stock price triggers in 2024
enabled us to optimize our capital structure, support healthy trading liquidityand simplify our 2025 financial reporting.
As we look ahead, our outlook for 2025 is aligned with our long-term objective of consistentlydelivering a Rule of X
performance between 45 and 50.â€Â The Companyâ€™s first-quarter and full-year expectations for 2025are as
follows:Â Â Â First-Quarter 2025 Expectations (as of 2/13/25) Â Full-Year 2025 Expectations (as of 2/13/25) ARR Â
\$406 million - \$411 million Â \$480 million - \$495 million Annual growth Â 22% - 24% Â 21% - 25% Revenue Â \$107
million - \$112 million Â \$480 million - \$490 million Annual growth Â 19% - 25% Â 20% - 22% Adjusted EBITDA Â \$22
million - \$24 million Â \$113 million - \$123 million Adjusted EBITDA margin Â ~21% Â 24% - 25% Â Conference Call

InformationÂ Cellebrite will host a live conference call and webcast later thismorning to review the Companyâ€™s financial results for the fourth quarter of 2024 and discuss its outlook for 2025. Pertinent detailsinclude:Â Date: Â Thursday, February 13, 2025 Time: Â 8:30 a.m. ET Call-In Number: Â 203-518-9783 / 800-267-6316 Conference ID: Â CLBTQ424 Event URL: Â <https://investors.cellebrite.com/events/event-details/cellebrite-q4-2024-fy-2024-financial-results-investor-call-webcast> Webcast URL: Â <https://edge.media-server.com/mmc/p/2oayuote> Â In conjunction with the conference call and webcast, historical financialtables and supplemental data will be available on the quarterly results section of Companyâ€™s investor relations website at <https://investors.cellebrite.com/financial-information/quarterly-results>.Â 3 Â Non-GAAP Financial Information and Key PerformanceIndicatorsÂ This press release includes non-GAAP financial measures. Cellebritebelieves that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAPnet income, non-GAAP EPS and Adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financialmeasures, are not prepared in accordance with GAAP.Â The Company believes that the non-GAAP financial measures provide amore meaningful comparison of its operational performance from period to period, and offer investors and management greater visibilityinto the underlying performance of its business. Mainly:Â â—Share-based compensation expenses utilize varyingavailable valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;Â â—Acquired intangible assets are valued at thetime of acquisition and are amortized over an estimated useful life after the acquisition, and acquisition-related expenses are unrelatedto current operations and neither are comparable to the prior period nor predictive of future results; Â â—To the extent that the above adjustments havean effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income; Â â—Tax expense, depreciation and amortization expensevary for many reasons that are often unrelated to the Companyâ€™s underlying performance and make period-to-period comparisons morechallenging; andÂ â—Financial instruments are remeasured accordingto GAAP and vary for many reasons that are often unrelated to the Companyâ€™s current operations and affect financial income. Â 4 Â Â Each of our non-GAAP financial measures is an important tool for financialand operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measuresdo not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net incomeor any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or asan alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information thatis directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAPfinancial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAPfinancial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may havea material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for theforeseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees.In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangibleasset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchangerates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.Â A reconciliation of each of these non-GAAP financialmeasures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also availableon our website at <https://investors.cellebrite.com>.Â In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because weare unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-basedpayments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.Â This press release also includes key performance indicators, includingannual recurring revenue and dollar-based retention rate.Â Annual recurring revenue (â€œARRâ€) is defined as the annualizedvalue of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the endof that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenueof the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing thecontractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue,deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impactedby contract start and end dates and renewal rates.Â Dollar-based net retention rate (â€œNRRâ€) is calculated bydividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers witha valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from thesame customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.Â 5 Â Â References to Websites andSocial Media PlatformsÂ References to information includedon, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information containedat or available through such websites or social media platforms, and you should not consider such information to be part of this pressrelease.Â Caution Regarding Forward Looking Statements Â This document includes â€œforward-looking statementsâ€ withinthe meaning of the â€œsafe harborâ€ provisions of the United States Private Securities Litigation Reform Act of 1995. Forwardlooking statements may be identified by the use of words such as â€œforecast,â€ â€œintend,â€ â€œseek,â€ â€œtarget,â€ â€œanticipate,â€ â€œwill,â€ â€œappear,â€ â€œapproximate,â€ â€œforesee,â€ â€œmight,â€ â€œpossible,â€ â€œpotential,â€ â€œbelieve,â€ â€œcould,â€ â€œpredict,â€ â€œshould,â€ â€œcould,â€ â€œcontinue,â€ â€œexpect,â€ â€œestimate,â€ â€œmay,â€ â€œplan,â€ â€œoutlook,â€ â€œfutureâ€ and â€œprojectâ€ and other similar expressions that predict, project or indicate future events or trendsor that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financialinformation for the first quarter of 2025 and for fiscal year 2025 and certain statements such as, multiple macro tailwinds that the Companybelieves show no signs of dissipating; the Company moves into 2025 with plans to advance its market and technology leadership, sustaints top-line expansion and continue generating attractive profit margins and robust free cash flow; and the Companyâ€™s outlook for2025 being aligned with its long-term objective of consistently delivering a Rule of X performance between 45 and 50. Such forward-lookingstatements including those with respect to 2025 revenue and annual recurring revenue, profitability and earnings as well as commentaryassociated with future performance, strategies, prospects, and other aspects of Cellebriteâ€™s business are based on current expectationsthat

are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled "Risk Factors" in Cellebrite's annual report on Form 20-F filed with the SEC on March 21, 2024 and as amended on April 12, 2024, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A 6 A About Cellebrite A Cellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital intelligence and accelerating justice in communities around the world. Cellebrite's AI-powered Case-to-Closure (C2C) platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies and businesses rely on the Company's cloud-ready digital forensic and investigative solutions to close cases faster and safeguard communities. To learn more, visit us at www.cellebrite.com. <https://investors.cellebrite.com> and find us on social media.

@Cellebrite.Â Contacts:Â Investors RelationsÂ Andrew Kramer Vice President, Investor Relations investors@cellebrite.com+1 973.206.7760Â MediaÂ Victor Cooper Sr. Director of Corporate Communications + Content Operations Victor.cooper@cellebrite.com+1 404.804.5910Â 7 Â Cellebrite DI Ltd. Fourth-Quarter 2024 Results Summary (U.S Dollars in thousands) Â Â For the three months endedÂ Â For the year endedÂ Â December 31,Â Â December 31,Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Â Â Â RevenueÂ Â 109,049Â Â 93,013Â Â 401,203Â Â 325,110Â Gross profitÂ Â 91,425Â Â 78,097Â Â 338,610Â Â 271,879Â Gross marginÂ Â 83.8%Â Â 84.0%Â Â 84.4%Â Â 83.6% Operating incomeÂ Â 15,727Â Â 14,999Â Â 56,906Â Â 33,237Â Operating marginÂ Â 14.4%Â Â 16.1%Â Â 14.2%Â Â 10.2% Net income (loss)Â Â 19,269Â Â (14,647)Â Â (283,007)Â Â (81,100) Cash flow from operating activitiesÂ Â 65,967Â Â 43,828Â Â 132,171Â Â 102,058Â Â Â Â Â Â Â Â Â Â Â Â Non-GAAP Financial Data:Â Operating incomeÂ Â 26,928Â Â 20,982Â Â 92,119Â Â 55,282Â Â Â Operating marginÂ Â 24.7%Â Â 22.6%Â Â 23.0%Â Â 17.0% Net incomeÂ Â 26,123Â Â 21,999Â Â 97,761Â Â 60,926Â Adjusted EBITDAÂ Â 28,793Â Â 22,726Â Â 99,377Â Â 61,946Â Adjusted EBITDA marginÂ Â 26.4%Â Â 24.4%Â Â 24.8%Â Â 19.1%Â 8 Â Cellebrite DI Ltd. Condensed Consolidated Balance Sheets (U.S. Dollars in thousands) Â Â Â DecemberÂ 31,Â Â DecemberÂ 31,Â Â 2024Â Â 2023Â AssetsÂ Â Â Â Â Current assetsÂ Â Â Â Â Cash and cash equivalentsÂ \$191,659Â Â \$189,517Â Short-term depositsÂ Â 153,746Â Â 74,713Â Marketable securitiesÂ Â 101,818Â Â 38,693Â Trade receivables (net of allowance for credit losses of \$594 and \$1,583 as of December 31, 2024 and December 31, 2023, respectively)Â Â 82,358Â Â 77,269Â Prepaid expenses and other current assetsÂ Â 23,246Â Â 26,400Â Contract acquisition costsÂ Â 5,827Â Â 5,550Â InventoriesÂ Â 8,939Â Â 9,940Â Total current assetsÂ Â 567,593Â Â 422,082Â Â Â Â Â Non-current assetsÂ Â Â Â Â Â Â Other non-current assetsÂ Â 7,682Â Â 7,341Â Marketable securitiesÂ Â 36,601Â Â 28,859Â Deferred tax assets, netÂ Â 11,072Â Â 7,024Â Property and equipment, netÂ Â 16,995Â Â 15,896Â Intangible assets, netÂ Â 11,306Â Â 10,594Â Operating lease right-of-use assets, netÂ Â 10,604Â Â 14,260Â GoodwillÂ Â 28,714Â Â 26,829Â Total non-current assetsÂ Â 122,974Â Â 110,803Â Total assetsÂ \$690,567Â Â 532,885Â Â Â Â Â Â Â Liabilities and shareholders' equityÂ Â Â Â Â Current LiabilitiesÂ Â Â Â Â Trade payablesÂ \$11,077Â Â \$8,282Â Other accounts payable and accrued expensesÂ Â 63,330Â Â 44,845Â Deferred revenuesÂ Â 216,970Â Â 195,725Â Operating lease liabilitiesÂ Â 4,125Â Â 4,972Â Total current liabilitiesÂ Â 295,502Â Â 253,824Â Â Â Â Â Long-term liabilitiesÂ Â Â Â Â Other long-term liabilitiesÂ Â 6,954Â Â 5,515Â Deferred revenuesÂ Â 45,247Â Â 47,098Â Restricted Sponsor Shares liabilityÂ Â €"Â Â 47,247Â Price Adjustment Shares liabilityÂ Â €"Â Â 81,715Â Derivative warrant liabilitiesÂ Â €"Â Â 54,117Â Operating lease liabilitiesÂ Â 6,844Â Â 9,157Â Total long-term liabilitiesÂ Â 59,045Â Â 244,849Â Total liabilitiesÂ Â 354,547Â Â 498,673Â Â Â Â Â Shareholders' equityÂ Â Â Â Â Share capitalÂ Â *)Â *) Additional paid-in capitalÂ Â 498,883Â Â (84,896) Treasury share, NIS 0.00001 par value; 41,776 ordinary sharesÂ Â (85)Â Â (85) Accumulated other comprehensive incomeÂ Â 2,086Â Â 1,050Â

Reconciliation of GAAP to Non-GAAP Financial Information (U.S Dollars in thousands, except share and per share data)

For the three months ended December 31, 2024 (Unaudited) (Unaudited) (Unaudited) Net income (loss) \$19,269 \$(14,647) \$(283,007) \$(81,100) Issuance expenses \$ 19,269 \$ 5,060 \$ 30,575 \$ 18,998 Amortization of intangible assets \$ 864 \$ 871 \$ 3,349 \$ 3,347 Acquisition-related costs \$ 52 \$ 221 \$ 45 Tax (income) expense \$(4,347) \$(252) \$(4,049) Finance expense from financial derivatives \$ 633 Non-GAAP net income \$ 26,123 \$ 21,999 \$ 97,761 \$ 60,926 Non-GAAP Earnings per share: Basic \$ 0.11 \$ 0.12 \$ 0.45 \$ 0.31 Diluted \$ 0.10 \$ 0.11 \$ 0.42 \$ 0.28 Weighted average shares outstanding: Basic \$ 233,248 \$ 45 \$ 194,440,674 \$ 209,471,827 \$ 190,154,549 Diluted \$ 250,539,405 \$ 207,110,826 \$ 227,258,731 \$ 206,194,081 For the three months ended December 31, 2024 (Unaudited) (Unaudited) Net income (loss) \$19,269 \$(14,647) \$(283,007) \$(81,100) Financial (income) expense, net \$(4,170) \$ 27,344 \$ 332,890 \$ 108,800 Tax expense \$ 628 \$ 2,302 \$ 7,023 \$ 5,537 Issuance expenses \$ 19,269 \$ 5,060 \$ 30,575 \$ 18,998 Amortization of intangible assets \$ 864 \$ 871 \$ 3,349 \$ 3,347 Acquisition-related costs \$ 52 \$ 221 \$ 45 Depreciation expenses \$ 1,865 \$ 1,744 \$ 7,258 \$ 6,664 One-time expense \$ 1,068 \$ 1,068 \$ 1,068 \$ 1,068 Adjusted EBITDA \$ 28,793 \$ 22,726 \$ 99,377 \$ 61,946 \$ 13